SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts

Surmodics (SRDX) reported fiscal Q3 2025 adjusted EPS of 6 cents, significantly exceeding analyst expectations and reversing a year-ago loss, which led to an 8.5% stock gain. While total revenue declined 2.6% to $29.6 million, primarily due to lower SurVeil DCB sales and license fees, this was partially mitigated by strong growth in its Pounce thrombectomy platform and IVD segment, despite a 116 basis point gross margin contraction. The company subsequently raised its fiscal 2025 revenue guidance and narrowed its adjusted loss per share outlook, indicating a more optimistic forward view despite product portfolio shifts.

Analysis

Surmodics (SRDX) reported a mixed but strategically positive third quarter for fiscal 2025, marked by a significant bottom-line outperformance that drove an 8.5% share price increase. The company posted an adjusted EPS of 6 cents, starkly beating the consensus estimate of a 21-cent loss and reversing a 27-cent loss from the prior year. This was achieved despite a 2.6% year-over-year revenue decline to $29.6 million. The revenue contraction was driven by the Medical Device segment, which fell 4.9%, primarily due to a $1.7 million drop in SurVeil DCB product sales from lower demand via its partner Abbott, and the cessation of SurVeil license fee revenue. However, this weakness was offset by positive momentum in other areas, notably strong growth from the Pounce thrombectomy device platform and a 5.7% sales increase in the In Vitro Diagnostics (IVD) segment. A key concern is the erosion of profitability at the gross level, with the gross margin contracting by 116 basis points to 70.9%. Despite this, the company's revised full-year guidance is optimistic; management raised the revenue outlook to $116.5-$118.5 million and substantially narrowed the projected adjusted loss per share to a range of 20-35 cents. This signals strong confidence in its product pipeline to successfully navigate the transition away from its declining SurVeil revenue stream.

Key Decisions for Investors

• Investors should weigh the significant earnings beat and improved full-year guidance against the fundamental challenge of a 2.6% year-over-year revenue decline and a 116 basis point gross margin contraction.
• Monitor the sales trajectory of the Pounce thrombectomy platform and IVD segment in coming quarters, as their ability to accelerate growth is critical to offsetting the planned decline in SurVeil revenues and validating the company's strategic pivot.
• Given the lower demand from partner Abbott for SurVeil products, any updates on this commercial relationship or new distribution developments for other products should be considered a key catalyst or risk factor.